HLA-E Antibody (MEM-E/02): sc-51621
- HLA-E Antibody (MEM-E/02) is a mouse monoclonal IgG1, cited in 7 publications, provided at 100 µg/ml
- raised against recombinant human HLA-E denatured heavy chain
- recommended for detection of denatured heavy chain of HLA-E of human origin by WB, IP, IF and IHC(P)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for HLA-E Antibody (MEM-E/02). This work is in progress.
QUICK LINKS
SEE ALSO...
HLA-E Antibody (MEM-E/02) is a mouse monoclonal IgG1 antibody that detects HLA-E in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. HLA-E is a crucial component of the immune system, functioning primarily as a non-classical major histocompatibility complex (MHC) class I molecule that presents a limited set of peptides to natural killer (NK) cells and CD8+ T lymphocytes. This selective peptide presentation is vital for immune regulation, as HLA-E plays a significant role in maintaining tolerance and preventing autoimmunity by interacting with inhibitory receptors on NK cells, thereby modulating their activity. The structure of HLA-E, which consists of a heavy chain that forms a heterodimer with β-2-Microglobulin, allows HLA-E to bind specific leader peptides derived from other MHC class I molecules, facilitating the recognition of healthy versus stressed or infected cells. By understanding the structural intricacies of HLA-E, researchers can better appreciate HLA-E′s importance in immune surveillance and the potential implications for therapeutic interventions in diseases such as cancer and viral infections. Anti-HLA-E antibody (MEM-E/02) is an essential tool for studying these critical immune processes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HLA-E Antibody (MEM-E/02) References:
- HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. | Gornalusse, GG., et al. 2017. Nat Biotechnol. 35: 765-772. PMID: 28504668
- Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition. | Pereira, BI., et al. 2019. Nat Commun. 10: 2387. PMID: 31160572
- Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids. | Xu, H., et al. 2022. Cell Mol Immunol. 19: 527-539. PMID: 35039632
- NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. | Salomé, B., et al. 2022. Cancer Cell. 40: 1027-1043.e9. PMID: 36099881
- Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. | Liu, X., et al. 2023. Cancer Cell. 41: 272-287.e9. PMID: 36706761
- Intracellular trafficking of HLA-E and its regulation. | He, W., et al. 2023. J Exp Med. 220: PMID: 37140910
- HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses. | Lin, Z., et al. 2023. Nat Immunol. 24: 1087-1097. PMID: 37264229
- High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation. | Huisman, BD., et al. 2023. Nat Commun. 14: 4809. PMID: 37558657
- Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis. | Jost, S., et al. 2023. Sci Immunol. 8: eadi3974. PMID: 38064568
- Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. | Tsao, HW., et al. 2024. Immunity. 57: 2863-2878.e12. PMID: 39561763
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HLA-E Antibody (MEM-E/02) | sc-51621 | 100 µg/ml | $322.00 |